ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,996.66
1.00%
Dow Jones
43,487.83
0.78%
US Dollar vs MXN
20.76806
-0.14%
Brent Oil
79.775
-0.55%
Bitcoin
102,323.52
1.30%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Europa
  5. EU

  6. Sanofi (SAN) Cotización

Sanofi

Sanofi (SAN)

Sagalio Energy Ltd
Sant Uk.10te%
Banco Santander SA
98.19
0.00
(0.00%)
Cerrado 20 Enero 10:30AM
Delayed by 15 minutes

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Estadísticas y detalles clave

Último Precio
98.19
Postura de Compra
98.00
Postura de Venta
99.00
Volume Operado de la Acción
0.00
0.00 Rango del Día 0.00
84.93 Rango de 52 semanas 106.14
Capitalización de Mercado [m]
122.997B
Precio Anterior
98.19
Precio de Apertura
-
Hora
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
1,567,854
Acciones en circulación
1,252,640,466
Rendimiento del Dividendo
11.28%
Ratio Precio/Utilidad
22.78
Beneficio por acción (BPA)
4.31
turnover
43.07B
Beneficio neto
5.4B

Acerca de Sanofi

Sector
Health & Allied Services,nec
Industria
Pharmaceutical Preparations
Sitio web
www.sanofi.com
Sede
Paris, Paris, Fra
Fundado
1994
Sanofi is listed in the Health & Allied Services sector of the Euronext with ticker SAN. The last closing price for Sanofi was 98.19 €. Over the last year, Sanofi shares have traded in a share price range of 84.93 € to 106.14 €.

Sanofi currently has 1,252,640,466 shares in issue. The market capitalisation of Sanofi is 123.00 € billion. Sanofi has a price to earnings ratio (PE ratio) of 22.78.

SAN Últimas noticias

Más noticias

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Novembre 2024

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Novembre 2024 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II...

15 Enero 2025
UK Regulatory

Sanofi: Information concerning the total number of voting rights and shares – November 2024

Sanofi: Information concerning the total number of voting rights and shares – November 2024 Information concerning the total number of voting rights and shares, provided pursuant to article L...

15 Enero 2025
UK Regulatory

Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma

Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma Approval based on positive pivotal ICARIA-MM phase 3 study using the...

13 Enero 2025
GlobeNewswire Inc.

Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma

Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma New Sarclisa subcutaneous formulation met co-primary endpoints in the...

09 Enero 2025
UK Regulatory

Communiqué de presse : La nouvelle formulation sous-cutanée du Sarclisa a satisfait aux co-critères d’évaluation primaires de l’étude de phase III IRAKLIA dans le myélome multiple

Communiqué de presse : La nouvelle formulation sous-cutanée du Sarclisa a satisfait aux co-critères d’évaluation primaires de l’étude de phase III IRAKLIA dans le myélome multiple La nouvelle...

09 Enero 2025
UK Regulatory

Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma

New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma Sarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary...

09 Enero 2025
GlobeNewswire Inc.

Communiqué de presse : Sanofi lance un programme de phase III pour son vaccin VPC21 et élargit sa collaboration avec SK Bioscience afin de développer une nouvelle génération de vaccins pneumococciques conjugués

Communiqué de presse : Sanofi lance un programme de phase III pour son vaccin VPC21 et élargit sa collaboration avec SK Bioscience afin de développer une nouvelle génération de vaccins...

23 Diciembre 2024
UK Regulatory

Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines

Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines Sanofi initiates phase 3 program for...

23 Diciembre 2024
UK Regulatory

Press Release: Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines

Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines Pneumococcal disease remains a major global health...

23 Diciembre 2024
GlobeNewswire Inc.

Presse release: Jean-Paul Kress to join Sanofi's Board of Directors

Presse release: Jean-Paul Kress to join Sanofi's Board of Directors Jean-Paul Kress to join Sanofi's Board of Directors Paris, December 19, 2024. Sanofi's Board of Directors is pleased to...

19 Diciembre 2024
UK Regulatory
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
13.223.3905443824494.97100.1293.06182251996.45749613DE
47.187.8892429403491.01100.1290.88131919595.21196322DE
12-2.93-2.89754746835101.12101.987.5156785493.62552359DE
264.995.3540772532293.2106.1487.5150188997.1721549DE
524.484.7807064347593.71106.1484.93147222793.41069134DE
1566.917.5701139351491.28106.6676.45173964292.83941618DE
2606.186.7166612324792.01106.6667.65193803689.43514941DE

SAN - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Sanofi?
El precio actual de las acciones de Sanofi es 98.19 €
¿Cuántas acciones de Sanofi están en circulación?
Sanofi tiene 1,252,640,466 acciones en circulación
¿Cuál es la capitalización de mercado de Sanofi?
La capitalización de mercado de Sanofi es EUR 123B
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Sanofi?
Sanofi ha negociado en un rango de 84.93 € a 106.14 € durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Sanofi?
El ratio precio/beneficio de Sanofi es 22.78
¿Cuál es el ratio de efectivo a ventas de Sanofi?
El ratio de efectivo a ventas de Sanofi es 2.86
¿Cuál es la moneda de reporte de Sanofi?
Sanofi presenta sus resultados financieros en EUR
¿Cuál es el último ingresos anual de Sanofi?
El último ingresos anual de Sanofi es EUR 43.07B
¿Cuál es el último beneficio anual de Sanofi?
El último beneficio anual de Sanofi es EUR 5.4B
¿Cuál es la dirección registrada de Sanofi?
La dirección registrada de Sanofi es 46, AVENUE DE LA GRANDE ARMEE, PARIS, PARIS, 75017
¿Cuál es la dirección del sitio web de Sanofi?
La dirección del sitio web de Sanofi es www.sanofi.com
¿En qué sector industrial opera Sanofi?
Sanofi opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
DRVDSDrone Volt
0.0039 €
(3,800.00%)
774.48k
GTRDSGroupe Tera DS
0.0585 €
(800.00%)
3.27k
ALCYBCybergun
0.0002 €
(100.00%)
3.98M
DMSBSDiagnostic Medical Systems
0.0075 €
(87.50%)
129.59k
NICBSNicox SA
0.0265 €
(50.57%)
979
MLSMLSmalto
0.014 €
(-33.33%)
1.62k
ALVERVergnet
0.0015 €
(-21.05%)
97.17M
MLIDSIds
0.364 €
(-19.11%)
1.12k
MCPGrupo Media Capital Sgps Sa
1.62 €
(-19.00%)
3
ALBOOBOOSTHEAT
0.063 €
(-15.78%)
70.91k
ATOAtos SE
0.002 €
(-4.76%)
2.53B
ALVERVergnet
0.0015 €
(-21.05%)
97.17M
BCPBanco Comercial Portugues SA
0.4988 €
(0.79%)
69.25M
EDPEDP SA
3.149 €
(1.22%)
13.56M
VIVVivendi SE
2.546 €
(-1.01%)
8.93M

Discusión

Ver feed completo
BeachBum BeachBum 3 minutos hace
You said 75 mil coming off ask a few weeks ago.
PSRU
gitreal gitreal 5 minutos hace
Okay, you got me to go back and re-read the CMC PR. I still see only the info about the financial deal with NBRI for the mill. Nothing about the mill being fully permitted or in full operations, etc.

https://www.globenewswire.com/news-release/2025/01/15/3009809/0/en/CMC-Metals-Esta
CMC NBRI
StockItOut StockItOut 7 minutos hace
No end of story! Biza hac a Xeriant Europe company before Duffy n Crew took Banjo & Matilda to change name to Xeriant, Inc., where then Xeriant, Inc. partnered with Xeriant Europe s.r.o. which had the name well prior.
XERI
mascale mascale 7 minutos hace
Comparing, only waterchaser poster knows the names of persons in outsourced former contactor offices(?).
HIRU
bwrbad bwrbad 10 minutos hace
bandwagon
RXRX
TightCoil TightCoil 12 minutos hace
Yes, We should sail,
Hoist The Main Sail
Hoist the Spinnaker
Catch Some Wind
FNMA
mascale mascale 15 minutos hace
The illiterate contrary posters fail to notice over $13.0 mil. cash in Q3 report and completion of successful Regulation S stock sales in 12/9 report--". . .we are proud to share that we have successfully secured partnerships with offshore investors through a Regulation S offering." Now Tasmanian mi
HIRU
TightCoil TightCoil 15 minutos hace
Reparations and Re-Listing on Big Board
Sing It Out - Shout It Out
Reparations and Re-Listing - Sing It
Reparations and Re-Listing - Shout It
FNMA
joeycav11 joeycav11 15 minutos hace
My take away from new regulations allowing MHRA use of real world evidence is that the data collected from treatments other types of cancer that used DC Vax via the compassionate care program can be used for submission of approvals for these new indications.
NWBO
Top Penny Top Penny 17 minutos hace
Probably picking up 20 million this coming week
PSRU
WiseYoda WiseYoda 18 minutos hace
Classic head fake….XRP will change direction once it finishes its course. Watch how it will change as were moving sideways now.
XRPUSD
jeunke22 jeunke22 19 minutos hace
Now that everybody received acknowledgment of their issues and frustrations with management , bonuses and perceived or real operational issues, can we go forward and concentrate at the huge opportunity in a civilized way?
The technology is real, the market is huge, new leadership is meant t
LWLG
Jack Torrance Jack Torrance 20 minutos hace
And I submit these documents through the "evidence" submittal part of the website?
ENZC
wadegarret wadegarret 21 minutos hace
COHR. CRMD, GERN, AESI, FEIM

A good 5 stocker. Two small caps. and three mid caps. GERN makes no money, but a bet on a drug that only has one competitor in the entire world to treat a deadly anemia. All 5 are good values imo
COHR CRMD GERN
TightCoil TightCoil 23 minutos hace
Your language/words are uncannily
similar to Rick Nagra. Say it isn't so.
FNMA
Truenorth2016 Truenorth2016 24 minutos hace
Looking forward to the next GCAN PR. Looking at other stocks with really good news and not running makes me believe there is no more teamwork left in the OTC. Been here on this board since 2015 and it feels like someone died coming to this platform. I mean most traders either changed their names or
GCAN
TightCoil TightCoil 27 minutos hace
Fannie and Freddie Shareholders from Sept. 5, 2008
to the day the NWS was imposed in 2012

Deserve Major Reparations - minimum $5 - $7 per share - REPARATIONS
SING IT - REPARATIONS - Whatta We Want - REPARATIONS - SING IT!
FNMA
Flexplate Flexplate 29 minutos hace
Wrong, go read the full statement then come back.
NBRI
cojoboy cojoboy 30 minutos hace
Sorry my bro..it hurts..☺😑😑😑😑😑
IGPK
along4zride along4zride 31 minutos hace
Breaking !! Excerpts from upcoming speech leaked . I caught it on my secret shortwave overseas ham radio channel . " We have front row Fannie's all over the place . During the next four years I will be fighting for them . We are on the eve of taking back the GSE's from government control and I am go
FNMA
Top Penny Top Penny 33 minutos hace
AI Overview
Learn more
https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcQgcgjC9tQM8URj6VCmN8VAipVcR-27V8_KWE-YbcElW_6euBAJ
Valiant Eagle Inc. (OTC:PSRU) is a company that is developing a Zelda movie. The movie is a biopic starring Jennifer Lawrence.
What's happening
PSRU
Top Penny Top Penny 36 minutos hace
Your bs is done with IBIO Sir!!!
IBIO

Su Consulta Reciente

EU
SAN
Sanofi
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados